Biotech

To develop RNA medicines targeting a proprietary bundle of tumor antigens, Epitopea is tapping nucleic acid delivery specialist Genevant Sciences in a deal worth up to $123.5 million

Pyxis Oncology is shelving a clinical-stage monoclonal antibody to focus on its lead antibody-drug conjugate (ADC) after sharing preliminary results for the ADC last month.

A phase 3 trial of Novo Nordisk's next-generation obesity prospect CagriSema has failed to achieve the level of weight loss targeted by executives, prompting investors to wipe 19% off the value of the Danish drugmaker.

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry.

Nerve stimulation company electroCore has signed an agreement to acquire NeuroMetrix and its Quell wearable device aimed at fibromyalgia and chronic pain.

The failure of a myeloid leukemia drug in a phase 3 trial in China isn't a shock to Apollomics, which had already given up on the E-selectin inhibitor.

As Cytokinetics' aficamten awaits approval decisions from regulators in the U.S. and China, Sanofi has picked up China rights to the cardiovascular candidate.

A turbulent month at Applied Therapeutics is being capped off with the departure of CEO and chair Shoshana Shendelman, Ph.D. , mere days after she and the company were named in a proposed class action lawsuit.

Clinical research firm Javara has laid off staff as part of a restructuring, a spokesperson confirmed to Fierce Biotech in an email.

Galectin Therapeutics' stock has halved since the company revealed its investigational drug failed to significantly reduce enlarged veins for people with liver scarring.